Skip to Content

Clinical Trial Details

A Phase 3, Double-Blind Randomized Study To Compare The Efficacy And Safety Of Rituximab Plus Lenalidomide (Cc-5013) Versus Rituximab Plus Placebo In Subjects With Relapsed/Refractory Indolent Lymphoma (AUGMENT Trial)

IRB Protocol Number
ACCRU RU051305S Celgene CC-55013-NHL-007

Clinical Trial Categories

  • Lymphoma/Lymph Node/Leukemia/Blood-related Cancers
Barbara Beauchemin, RN, BSN at 603-224-2556


  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000